Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Muno-IgY** is an ultra-pure, all-natural antibody-based supplement derived from hen egg yolk, containing immunoglobulin Y (IgY) antibodies. These antibodies target and bind pathogenic microbes and toxins in the gastrointestinal tract, helping neutralize and remove unwanted bacteria while preserving beneficial commensal flora[3][5][2]. The mechanism of action is passive immunization at the gut mucosa; IgY inhibits microbial adhesion, induces pathogen agglutination, neutralizes toxins, and supports barrier integrity[3][2][6]. The supplement shows potential for improving immune and gut health, reducing upper respiratory tract infection rates, and managing gut dysbiosis and leaky gut syndrome[3][5]. Muno-IgY is developed and manufactured by IGY Immune Technologies & Life Sciences, which uses a proprietary process for high-purity extraction. It is marketed for dietary supplement use and designated self-affirmed GRAS for safety as per US Title 21 Code of Federal Regulations[2]. Clinical studies in healthy adults have been conducted to assess safety, effectiveness, and bioavailability[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Muno-IgY.